Professor John Gribben - Treating patients with chronic lymphocytic leukaemia (CLL)
Prof. Gribben's highlights from ASH 2016
Professor John G. Gribben: iwCLL 2017
ASH 2019 Interview - Prof John Gribben and Deborah Sims - Overview of CLL treatment
Where will leukemia research go next?
John Gribben’s ASH 2019 CLL and lymphoma highlights
BCR inhibitors improving CLL patient outcomes
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
Highlights of ASH in CLL
Exciting drug developments in chronic lymphocytic leukemia (CLL)
Where are we with precision medicine for CLL?
What are the economics of treating CLL?
The current status of CLL treatment and how clinical practice will change
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
John Gribben - CAR-T Therapy
Finding the right clinical trial: a message for the CLL community
CAR T-cell therapy: a field moving fast
Treating chronic lymphocytic leukemia like blood pressure